The FDA announced that it granted two additional approvals to Syneron Medical Ltd. and its North American subsidiary, Syneron Inc., for the company's hair removal and skin rejuvenation devices.
HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52
The Cutaneous Connection: JAK Inhibitor Safety for Treating AD
Losing a Malpractice Case May Depend on Where You Live
The Cutaneous Connection: Treating Atopic Dermatitis in the Winter
The Role We Play in Addressing Racial Disparity in Dermatology
The Mainstream Patient: February 2